Hyperfine, Inc. (HYPR) stock
HYPRNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3021% below fair value
$0.61−0.02 (-3.05%)
Close on Nov 16, 2026Market cap $64.70MP/E –Yield –
Hyperfine r&d expenses
Research and development expenses are spending on new products and technology.
Hyperfine's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.58M, down 24.2% year over year. For fiscal 2025 it was $17.45M, down 22.4% from the year before. The highest annual figure on record is $28.16M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.45M | -22.4% |
| FY2024 | Dec 31, 2024 | $22.50M | +0.0% |
| FY2023 | Dec 31, 2023 | $22.49M | -20.1% |
| FY2022 | Dec 31, 2022 | $28.16M | +9.0% |
| FY2021 | Dec 31, 2021 | $25.84M | +77.1% |
| FY2020 | Dec 31, 2020 | $14.59M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.87M | -14.9% |
| Q1 FY2026 | Mar 31, 2026 | $3.85M | -23.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.83M | -25.1% |
| Q3 FY2025 | Sep 30, 2025 | $4.05M | -31.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.54M | -23.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.04M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $5.11M | -14.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.87M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | $5.96M | +11.8% |
| Q1 FY2024 | Mar 31, 2024 | $5.57M | +2.0% |
| Q4 FY2023 | Dec 31, 2023 | $5.96M | +14.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.74M | -21.8% |
| Q2 FY2023 | Jun 30, 2023 | $5.33M | -26.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.46M | -34.5% |
| Q4 FY2022 | Dec 31, 2022 | $5.22M | -41.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.34M | +14.0% |
| Q2 FY2022 | Jun 30, 2022 | $7.27M | +20.3% |
| Q1 FY2022 | Mar 31, 2022 | $8.33M | +86.3% |
| Q4 FY2021 | Dec 31, 2021 | $8.89M | – |
| Q3 FY2021 | Sep 30, 2021 | $6.44M | – |
| Q2 FY2021 | Jun 30, 2021 | $6.04M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.47M | – |
See a number that looks wrong?